Cholesterol drug tested to stop stroke worsening
NCT ID NCT07301372
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving the cholesterol-lowering drug evolocumab within 24 hours after clot-busting treatment (thrombolysis) can prevent early neurological decline in people with acute ischemic stroke. 132 participants were randomly assigned to receive evolocumab plus standard care or standard care alone. The main goal was to see if evolocumab reduced worsening of stroke symptoms in the first week.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
evolocumab (a cholesterol-lowering drug)
What this could lead to
If it works, this could point toward a way to prevent early neurological decline after a stroke, potentially improving recovery.
What could go wrong
This is a small, single-center, open-label trial, so results may not be definitive or apply broadly. The drug also does not eliminate the need for ongoing statin therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Neurology
Xuzhou, Jiangsu, China